Mogħdija tan-navigazzjoni

Għodod addizzjonali



    Profil tar-reġistrant

Grünenthal GmbH

Numru ta’ identifikazzjoni fir-Reġistru: 67826544528-01
Data Reġistrazzjoni: 14/11/2010 18:46:49

L-informazzjoni dwar din l-entità kienet mibdula l-aħħar fi: 12/02/2015 19:14:26
Id-data tal-aħħar aġġornament annwali kienet: 12/02/2015 19:14:26
L-aġġornament li jmiss mistenni mhux aktar tard minn : 12/02/2016

    Reġistrant: Organizzazzjoni jew individwu li jaħdem għal rasu

Grünenthal GmbH

Grünenthal

Gesellschaft mit beschränkter Haftung

    Taqsima ta’ reġistrazzjoni

II - Lobbyists u assoċjazzjonijiet kummerċjali/ta' negozju/professjonali interni

Kumpaniji u gruppi

    Dettalji personali

Zieglerstraße, 6
Aachen D-52099
IL-ĠERMANJA

(+49) 241 569 0

    Persuna b'responsabbiltà legali

Sinjur  Eric-Paul Pâques

Chairman of the Corporate Executive Board

    Persuna li tiegħu ħsieb ir-relazzjonjiet mal-UE

Sinjur  Konrad Labuschagne

Governmental Affairs and Health Policy

    Għanijiet u missjonijiet

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company in the field of pain and thus to be a leader in therapy innovation.

Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 27 percent of revenues in 2013. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

Altogether, the Grünenthal Group has affiliates in 25 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2013, Grünenthal achieved revenues of €901 mn.

More information: www.grunenthal.com

Dinji

    Attivitajiet speċifiċi koperti mir-Reġistru

Grünenthal supports the multistakeholder platform "Societal Impact of Pain" (SIP, www.sip-platofrm.eu). Furthermore Grünenthal activities in Brussels deal with issues related to healthcare, pain care, pharmaceuticals, innovation and research and intellectual property.


 

Le

Le

Le

Le

Le

Grünenthal supports the multistakeholder platform "Societal Impact of Pain" (SIP, www.sip-platofrm.eu). Furthermore Grünenthal activities in Brussels deal with issues related to healthcare, pain care, pharmaceuticals, innovation and research and intellectual property.

    Numru ta' persuni involuti fl-attivitajiet deskritti fil-kaxxa t'hawn fuq

50%: 1   25%: 2

3

1

    Persuni akkreditati għall-aċċess fil-bini tal-Parlament Ewropew

L-ebda persuna akkreditata

    Oqsma ta’ interess

  • Affarijiet Ekonomiċi u Finanzjarji
  • Affarijiet ġenerali u istituzzjonali
  • Dwana
  • Għajnuna umanitarja
  • Impjiegi u affarijiet soċjali
  • Intrapriżi
  • Kompetizzjoni
  • Netwerks trans-Ewropej
  • Politika reġjonali
  • Riċerka u teknoloġija
  • Saħħa pubblika
  • Suq Intern
  • Tassazzjoni
  • Tkabbir

    Sħubija u affiljazzjoni

Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

    Dejta finanzjarja

01/2013  -  01/2014

< 9,999 €

Ebda finanzjament riċevut mill-istituzzjonijiet tal-UE fl-aħħar sena finanzjarja magħluqa.

    Kodiċi ta’ kondotta

B'din ir-reġistrazzjoni, l-organizzazzjoni ffirmat il-Kodiċi ta' Kondotta tar-Reġistru għat-Trasparenza.